✦ LIBER ✦

Tolcapone in elderly patients with Parkinson’s disease: A prospective open-label multicenter non-interventional trial

✍ Scribed by Georg Ebersbach; Alexander Storch

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 272 KB
Volume: 49
Category: Article
ISSN: 0167-4943
DOI: 10.1016/j.archger.2008.08.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S-adenosyl-methionine improves depressio

S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial

✍ Alessandro Di Rocco; John D. Rogers; Richard Brown; Peter Werner; Teodoro Bottig 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 2 views

Test–Retest reliability of the Unified P

Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial

✍ Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale h

AFFECT: a prospective, open-label, multi

AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation

✍ Ulrich Tebbe; Ralph Oeckinghaus; Karl-Friedrich Appel; Hubertus Heuer; Hendrik H 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 267 KB

An open-label, multicentre clinical tria

An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

✍ M. M. Pinter; A. W. F. Rutgers; E. Hebenstreit; on behalf of the the study cente 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 198 KB

Safety and tolerability of rivastigmine

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)

✍ Jason T. Olin; Vinod Bhatnagar; Patricio Reyes; Barbara Koumaras; Xiangyi Meng; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## Objective Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild‐to‐moderate Alzheimer's disease (AD) and Parkinson's disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects an

A Multicenter, Prospective, Open Label,

A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma®5% DIF, the Next Generation of Flebogamma®

✍ Melvin Berger; The Flebogamma® 5% DIF Investigators 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 126 KB